SOLNA, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1 a ...
First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight ...
Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective ß2-agonists for the first time in metabolic disease First-in-class oral therapy ATR-258 mimics the effects of ...
First-in-class oral therapy ATR-258 mimics the effects of exercise - driving fat loss, increasing muscle, and improving metabolism - with broad potential as a novel treatment for muscle-sparing weight ...
Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic disease First-in-class oral therapy ATR-258 mimics the effects of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results